SIK3

Serine/threonine-protein kinase SIK3 · Q9Y2K2 · SIK3 on Sugi Atlas →

18,877 patent compounds predicted against SIK3, 12,998 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2236549	0.53	13/20
SCHEMBL1704876	0.91	12/20
SCHEMBL1705125	0.85	12/20
SCHEMBL1704509	0.82	12/20
SCHEMBL1704785	0.65	12/20
SCHEMBL1704413	0.64	12/20
SCHEMBL1705254	0.62	12/20
SCHEMBL2066261	0.60	12/20
SCHEMBL2067692	0.54	12/20
SCHEMBL1147178	0.56	9/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	8/20
Dasatinib Anhydrous (SCHEMBL8226)	0.98	8/20
Dasatinib Anhydrous (SCHEMBL1704366)	0.97	8/20
Dasatinib Anhydrous (SCHEMBL1705152)	0.97	8/20
Dasatinib Anhydrous (SCHEMBL1363032)	0.93	8/20
Dasatinib Anhydrous (SCHEMBL1362204)	0.89	8/20
Dasatinib Anhydrous (SCHEMBL1767233)	0.85	8/20
SCHEMBL1147002	0.52	8/20
SCHEMBL1147078	0.52	8/20
SCHEMBL2372126	0.47	8/20

Clinical trials — most relevant to SIK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
Non-surgical Periodontal Therapy and Myo-inositol in Polycystic Ovary Syndrome Women Having Chronic Periodontitis	PHASE2	UNKNOWN
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study	nan	WITHDRAWN
Does Protein Restriction Inhibit Prostrate Cancer Growth	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SIK3 binder may also engage these)

Protein	Name	Similarity
Q6P4S6	—	1.000	Q6P4S6 →
Q6NSM8	—	1.000	Q6NSM8 →
Q58NQ4	—	1.000	Q58NQ4 →
Q9H334	—	0.999	Q9H334 →
P23899	—	0.998	P23899 →
P83038	—	0.998	P83038 →
Q2EJA0	—	0.998	Q2EJA0 →
Q498D1	—	0.997	Q498D1 →
Q4VYR7	—	0.997	Q4VYR7 →
A0A8C0NGY6	—	0.997	A0A8C0NGY6 →
TFEB	Transcription factor EB	0.997	landscape →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.996	landscape →
P24610	—	0.996	P24610 →
Q6F2E4	—	0.996	Q6F2E4 →
Q4VYS1	—	0.996	Q4VYS1 →
Q9GZV5	—	0.996	Q9GZV5 →
P27889	—	0.996	P27889 →
Q7TN99	—	0.996	Q7TN99 →
BMP2K	BMP-2-inducible protein kinase	0.996	landscape →
Q91904	—	0.996	Q91904 →
Q03365	—	0.996	Q03365 →
HDAC5	Histone deacetylase 5	0.996	landscape →
P0CF24	—	0.996	P0CF24 →
P35680	—	0.996	P35680 →
Q9H329	—	0.996	Q9H329 →
Q5QL03	—	0.995	Q5QL03 →
Q812B1	—	0.995	Q812B1 →
Q9PSY4	—	0.995	Q9PSY4 →
A7MBB4	—	0.995	A7MBB4 →
Q80TZ9	—	0.995	Q80TZ9 →